Transposon Therapeutics
CA - San DiegoBiotechnology
Focus: Novel, orally administered therapies for the treatment of neurodegenerative and aging-related diseases
Transposon Therapeutics is a life sciences company focused on Novel, orally administered therapies for the treatment of neurodegenerative and aging-related diseases.
Profile data last refreshed Yesterday
Open Jobs
0
Data completeness
1/9 — Limited
Company HealthSolid
Pipeline
Early-stage
3 total
LOE Risk
Protected
No near-term cliffs
Hiring
0 open
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Pipeline & Clinical Trials
TPN-101, 400 mg/day
Amyotrophic Lateral SclerosisClinical Trials (1)
NCT04993755A Phase 2a Study of TPN-101 in Patients With C9ORF72 ALS/FTD
Phase 2Help build intelligence for Transposon Therapeutics
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.